PK/PD Study of Subcutaneous Cenderitide Infusion in CHF Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

November 30, 2011

Conditions
Heart FailureADHFChronic Heart FailureCHF
Interventions
DRUG

Cenderitide

Cenderitide is a novel rationally designed chimeric natriuretic peptide to be administered in this trial as either a subcutaneous injection or infusion.

OTHER

Placebo

Placebo will be administered as a 24-hour SQ infusion

Trial Locations (5)

32216

Jacksonville Center for Clinical Research, Jacksonville

55415

Hennepin County Medical Center, Minneapolis

66219

Analab Clinical Research, Inc., Lenexa

70006

Benchmark Research, Metairie

92780

Orange County Research Center, Tustin

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Integrium

INDUSTRY

lead

Nile Therapeutics

INDUSTRY